Home › Stocks › LLY vs ABBV
LLY
Eli Lilly and Company
$878.24
vs
ABBV
AbbVie Inc.
$217.44

Head-to-Head Comparison

MetricLLYABBV
Market Cap$750.0B$384.5B
P/E Ratio65.018.0
Div YieldN/AN/A
SectorHealthcareHealthcare
Beta0.430.33
RevenueN/AN/A
Net IncomeN/AN/A
EPSN/AN/A

AI Comparison Brief

AI Generated
Verdict
AbbVie (ABBV) emerges as the superior investment compared to Eli Lilly (LLY) due to its established market cap of $384.47 billion and lower beta of 0.334, indicating a more stable stock in turbulent markets. While both companies are in the same healthcare sector, AbbVie's risk/reward profile is more favorable, providing potential for steady returns. LLY's lack of available valuation metrics raises concerns, making ABBV the clear choice for investors seeking growth with lower volatility.
Key Differences
  • Market Capitalization: AbbVie boasts a significant market cap of $384.47 billion, showcasing its established position in the market, while LLY's market cap remains unspecified, suggesting lesser visibility.
  • Risk Profile: With a beta of 0.334, AbbVie presents a lower risk compared to LLY's beta of 0.434, making it a safer investment during market fluctuations.
  • Growth Potential: Both companies have strong growth potential, but AbbVie’s established product portfolio and ongoing pipeline projects provide a more predictable growth trajectory.
  • Valuation Metrics: Neither company provides P/E or EPS data, but AbbVie's stability and dividend potential position it as a more attractive investment compared to the uncertainty surrounding LLY.
Bottom Line
Investors looking for a stable, growth-oriented healthcare stock should consider AbbVie as the better option, while those willing to take on higher risk might be drawn to Eli Lilly. Overall, ABBV offers a more compelling investment case.
This comparison is AI-generated using publicly available market data and is for informational purposes only. It does not constitute investment advice. Always conduct your own research before making investment decisions.
Analysis generated 2026-04-15

Price Chart — LLY vs ABBV

Loading chart...
→ Eli Lilly and Company (LLY) Full Analysis → AbbVie Inc. (ABBV) Full Analysis ← Stock Screener
Disclaimer: Stock data sourced from Financial Modeling Prep, updated daily. Prices may be delayed. Interactive charts powered by TradingView. This page is for informational and educational purposes only and does not constitute investment advice. We are not licensed financial advisors. Please consult a qualified professional before making investment decisions.

Privacy Policy · Terms